GEN 40th Anniversary: Getting the Band Back Together

This webinar will give you sufficient understanding to classify new products and technologies containing human tissues or cells and to understand the impact of such products in a portfolio.

IGHV mutation analysis should be top of mind when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia, said Curtis A. Hanson, MD, in a CAP TODAY webinar made possible by a special educational grant from Diaceutics. Dr. Hanson, professor of laboratory medicine and pathology, Mayo Clinic College of Medicine, explained the structure and function of IGHV, the mutation assay, and the clinical value of mutation status. Here is an edited transcript of what he said.

Since the year of 2000, there’re 13 ADCs on the market and 9 of them were approved in the last three years. The enthusiasm of pharmaceutical and biotechnology companies for the research and development of ADC has been increasing.

Multi-Gene panel-based genetic testing has emerged as the standard of care for cancer genetic testing. This has led to the identification of TP53 mutations among individuals without classic personal or family histories of Li-Fraumeni syndrome. These mutations may be due to mosaicism, clonal hematopoiesis, or due to form fruste Li-Fraumeni syndrome. We will discuss how these findings are shaping clinical cancer genetics care and how they are leading to a re-evaluation of the epidemiology and penetrance of germline TP53 mutations.